<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60227">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01684735</url>
  </required_header>
  <id_info>
    <org_study_id>B322201213618</org_study_id>
    <nct_id>NCT01684735</nct_id>
  </id_info>
  <brief_title>Diffusion Weighted Magnetic Resonance Imaging of the Breast During Chemotherapy: Response Evaluation</brief_title>
  <official_title>Diffusion Weighted Magnetic Resonance Imaging of the Breast During Chemotherapy: Response Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the response to chemotherapy in breast cancer patients by the use of
      Diffusion-weighted magnetic resonance imaging of the breast before the start of
      chemotherapy, after one and 3 cycles of therapy and at the end of the therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Response to chemotherapy</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>outcome is the results of pathology after chemotherapy and surgery. Data will be collected for a period of 1 year.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>women with breast cancer and chemotherapy</arm_group_label>
    <description>women recently diagnosed with breast cancer and selected to start with neo-adjuvant chemotherapy (6 cycles) before surgery/therapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        women diagnosed with breast cancer and treated with neo-adjuvant chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  core biopsy with diagnosis of breast cancer

          -  start of neo-adjuvant chemotherapy

        Exclusion Criteria:

          -  magnetic resonance imaging incompatibility
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chantal Van Ongeval, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chantal Van Ongeval, MD,PhD</last_name>
    <phone>(0)16343746</phone>
    <phone_ext>+32</phone_ext>
    <email>chantal.vanongeval@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilde Vandenhoutte, Phd</last_name>
      <phone>(0)16343636</phone>
      <email>hilde.vandenhoutte@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Chantal Van Ongeval, MD,Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 12, 2012</lastchanged_date>
  <firstreceived_date>May 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Chantal Van Ongeval, MD, Phd</investigator_full_name>
    <investigator_title>MD,Phd</investigator_title>
  </responsible_party>
  <keyword>diffusion-weighted magnetic resonance imaging</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
